论文部分内容阅读
目的:观察黄芪注射液联合TP化疗方案治疗晚期卵巢癌的临床疗效及安全性。方法:将62例晚期卵巢癌患者随机分成两组,其中31人为治疗组,接受黄芪注射液联合TP治疗,31人采用TP治疗。从总效率、疾病控制、毒副反应等指标进行评价。结果:治疗组的总效率、疾病控制、骨髓抑制以及肝肾功能与对照组相比,差异无统计学意义(P>0.05);治疗组的中性粒细胞、心脏毒性、脱发、肌肉关节疼痛、胃肠道反应与对照组相比,差异有统计学意义(P<0.01)。结论:黄芪注射液联合TP化疗方案治疗晚期卵巢癌的临床疗效显著,降低了化疗的毒副反应。
Objective: To observe the clinical efficacy and safety of astragalus injection combined with TP chemotherapy in the treatment of advanced ovarian cancer. Methods: Sixty-two patients with advanced ovarian cancer were randomly divided into two groups, of which 31 were treated with astragalus injection plus TP and 31 were treated with TP. From the total efficiency, disease control, toxicity and other indicators of evaluation. Results: The total efficiency, disease control, bone marrow suppression and liver and kidney function of the treatment group were not significantly different from those of the control group (P> 0.05). The neutrophils, cardiotoxicity, hair loss, muscle and joint pain , Gastrointestinal reaction compared with the control group, the difference was statistically significant (P <0.01). Conclusion: Astragalus injection combined with TP chemotherapy in the treatment of advanced ovarian cancer has a significant clinical effect, reducing the side effects of chemotherapy.